Search This Blog

Tuesday, August 6, 2019

Fate Therapeutics EPS misses by $0.03, beats on revenue

Fate Therapeutics (NASDAQ:FATE): Q2 GAAP EPS of -$0.36 misses by $0.03.
Revenue of $2.82M (+173.8% Y/Y) beats by $1.73M.
Press Release
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)